H
EART FAILURE (HF) AND especially acute HF (AHF) are important causes of morbidity and mortality in the developed world. The high rate of rehospitalization, the unproductive years of life, and the price of treatment constitute an important economic burden. Little is known about acute and chronic HF in sub-Saharan Africa. 1 Recent studies [2] [3] [4] [5] suggested that the main underlying causes of HF are different in Africa, including some conditions that are almost unique, such as endomyocardial fibrosis and tuberculous pericarditis, 6, 7 as well as a high prevalence of peripartum cardiomyopathy and idiopathic dilated cardiomyopathy. 8 At the same time, with a nonuniform epidemiologic transition to a more Western way of living, prevalences of hypertension, obesity, and diabetes are increasing, particularly in urban centers, with a possible effect on the etiology of HF.
ment of AHF and morbidity and mortality among those with the disease in the African subcontinent.
METHODS

STUDY DESIGN AND CLINICAL SETTING
We conducted THESUS-HF as a prospective, multicenter, international observational survey in 12 cardiology centers from 9 countries in the southern, eastern, central, and western regions of sub-Saharan Africa. The countries and centers were selected on the basis of availability of a physician trained in clinical cardiology and echocardiography who had previously participated in research projects. Ethiopia, Kenya, and Senegal joined the study late, resulting in a shorter enrollment period.
INCLUSION AND EXCLUSION CRITERIA
Patients older than 12 years admitted with dyspnea as the main complaint and diagnosed with AHF based on symptoms and signs that were confirmed by echocardiography (de novo or decompensation of previously diagnosed HF) were enrolled in the present study. Exclusion criteria were acute ST-elevation myocardial infarction, severe known renal failure (patients undergoing dialysis or with a creatinine level of Ͼ4 mg/dL) (to convert to micromoles per liter, multiply by 88.4), nephrotic syndrome, hepatic failure, or another cause of hypoalbuminemia. Written informed consent was obtained from each subject who was enrolled into the study. Ethical approval was obtained from the ethical review board of the participating institutions, and the study conformed to the principles outlined in the Declaration of Helsinki.
DATA COLLECTION AND CASE DEFINITION
A comprehensive range of clinical data was collected on a standardized case report form. A detailed echocardiographic assessment of ventricular function, valvular structure and function, and regional wall abnormalities was performed. All echocardiographic procedures were undertaken by trained physicians, and measurements were made according to the American Society of Echocardiography Guidelines. 10 Electrocardiograms were read centrally by a cardiologist at Momentum Research, Inc, using standard reference ranges. 11 Laboratory evaluations provided by the local institution and intravenous and oral medications were recorded at admission and on days 1, 2, and 7 (or at discharge if earlier). Symptoms and signs of HF, vital signs, and laboratory test data (when indicated) were collected at baseline and through day 7 (or at discharge if earlier). The probable primary cause of HF was based on the European Society of Cardiology guidelines 12 and as recently applied in the chronic HF cohort of the Heart of Soweto Study. 13 Ischemic causes were determined on the basis of accepted criteria, such as history, or results of noninvasive (eg, electrocardiography, stress test) or invasive tests when available. Testing for human immunodeficiency virus infection was only performed when clinical findings raised suspicion and after patient consent was obtained.
Subjects underwent evaluation for symptoms and signs of HF and laboratory testing (when indicated) at the 1-and 6-month follow-ups. Information on readmissions and death, with respective reasons and cause, was collected through the 6-month followup. We initiated telephone contact with patients who could not attend additional clinic visits because they moved to a different location or to another province. Patients who could not be contacted were censored at the last available contact.
To better understand the changes in the pattern of AHF in Africa, the present cohort was classified as having endemic causes (group 1; ie, rheumatic heart disease, the cardiomyopathies, and infective causes, such as pericarditis and human immunodeficiency virus-associated cardiomyopathy), and emerging causes (group 2; ie, hypertension and ischemic heart disease).
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STATISTICAL ANALYSES
All data were processed at Momentum Research, Inc. Data were verified and analyzed using commercially available software (SAS, version 9.2; SAS Institute, Inc). Continuous data were presented as mean (SD) or median (interquartile range, ie, 25th and 75th percentiles). Continuous variables were compared using 2-tailed, 2-sample t tests and categorical variables using 2 tests. Sex-adjusted differences between patients with emerging and endemic causes were estimated using weighted least squares regression for dichotomous characteristics and ordinary linear regression for continuous characteristics. KaplanMeier estimates of mortality and readmission rates were provided. The time to the first event was considered; times for patients without the event of interest were censored at the earlier of the last date the patient was known to be alive or the period of interest.
RESULTS
BASELINE PATIENT CHARACTERISTICS ON ADMISSION
From July 1, 2007, to June 30, 2010, 1011 patients were enrolled in the study, for whom 1006 case report forms were received (Figure 1) . Table 1 shows the demographic and clinical presentation on admission for the entire cohort and compares men with women (50.8% of the cohort). Electrocardiographic strips were available for 814 patients. The most frequent arrhythmia was atrial fibrillation, which was found in 147 of 806 patients (18.2% Figure 2 shows the causes of HF in the entire study cohort. In some patients, more than 1 cause was identified. Table 2 shows the characteristics by endemic vs emerging HF causes and interaction of those causes with sex. Figure 3 shows the different causes of AHF by country.
CAUSES OF HF
THERAPIES FOR HF
The most commonly administered intravenous medication at admission was furosemide in 927 of 998 patients (92.9%), with use decreasing to only 215 of 938 patients (22.9%) at day 7 or discharge. The next commonly administered parenteral drugs on admission were digoxin in 13.7% and nitrates in 7.9%. Parenteral inotropes (ie, dopamine hydrochloride and dobutamine hydrochloride) were used in 5.0% and 5.1%, respectively, on admission. Mechanical ventilation was rarely used (0.6%). Figure 4 shows prescribed oral medications on admission and follow-up.
PATIENTS' FOLLOW-UP AND OUTCOMES
Of 1006 patients, 1-month follow-up assessments were completed for 578 (57.5%) and 6-month assessments for 461 (45.8%). A total of 159 of 1006 patients (15.8%) died without completing a 6-month assessment; an additional 316 (31.4%) had a last date known alive provided and were included in the analysis. The remaining 70 patients (7.0%) were lost to follow-up. Reasons for loss to follow-up were provided for 35 of these patients and included lack of telephone contact (2.3%), financial constraints (0.3%), unwillingness to come for follow-up (0.3%), lack of transportation to the site (Ͻ0.1%), and others, for example, transfer of care to other facilities (0.5%). Table 3 reports the main clinical outcomes observed in the study. The rate of death or readmission at 60 days was 15.4% ( Figure 5A) , and the estimated 6-month mortality rate was 17.8% ( Figure 5B ). Mortality rates were similar among countries, except that a somewhat lower rate was reported in the Ugandan center (6.3%).
COMMENT
To our knowledge, our data represent Africa's first and largest multinational prospective registry of AHF. This registry reveals a few unique characteristics of AHF in sub-Saharan Africa.
One of the most striking features of this cohort of African patients with AHF is the relative youth of the patients affected (median age, 55 years). In industrialized countries, AHF is a disease of the elderly, with a mean age of 72 years (median age, 66-70 years) 18 ; hence, the condition presents 2 decades earlier in sub-Saharan Africa. Acute HF therefore strikes patients in the prime of their lives in sub-Saharan Africa, with major economic implications because it affects the generation of breadwinners and caregivers. With respect to sex, despite the relative youth of the patients, the disease affects men and women equally, although the characteristics and causes differ by sex (Tables 1 and 2) , probably contributing to slight differences in outcomes (Table 3) .
Three important observations are worth noting about medical therapy for AHF (Figure 3) . First, we have observed a high incidence of the use of aspirin in patients with nonischemic HF in the sub-Saharan African region. In addition, the combination of hydralazine hydrochloride and nitrates, which has been shown to be effective in patients of African descent, 19, 20 is hardly ever used in the subSaharan region. Third, the rate of ␤-blocker use, even at follow-up, is relatively low. Although many patients in the present study have HF with preserved systolic function for which the use of ␤-blockers is less clearly indicated, the rate of ␤-blocker use in THESUS-HF is lower than that described in other regions. 18, 21, 22 These observations provide an opportunity to improve the quality of the care of patients with HF in the region. A larger randomized study investigating the combination treatment with hydralazine and nitrates vs placebo in Africans admitted with AHF will commence soon in the centers that participated in the THESUS-HF registry.
The cause of AHF remains predominantly nonischemic, with hypertension, rheumatic heart disease, and the endemic cardiomyopathies (ie, idiopathic dilated cardiomyopathy, peripartum cardiomyopathy, and endomyocardial fibrosis) accounting for 75.5% of the cases ( Figure 2 and Table 2 ). Although the rate of ischemic heart disease may have been underestimated owing to limited diagnostic tools, this finding is in striking contrast to registries in Europe or the United States, 18, 21, 22 where ischemic heart disease (a rarity in Africa) accounts for most of the cases. However, Africa is clearly facing an additional burden because, in addition to the high prevalence of endemic diseases, we are observing a high (and probably increasing) burden of emerging diseases, such as ischemic heart disease and hypertension, in particular in some countries ( Figure 3) . As socioeconomic changes continue to progress across the continent, the number of AHF cases (particularly in women) caused by noncommunicable forms of heart disease may further increase. Finally, human immunodeficiency virus infection, which can affect the myocardium in various ways, 23 is a common condition among patients with HF in Africa.
Whether the early introduction of antiretroviral therapy in human immunodeficiency virus-seropositive patients with HF and otherwise no indication for antiretroviral therapy will change their outcome remains to be established in future studies. 
